527. Development of a Bioengineered Recombinant Factor VIII Therapeutic Using a Lentiviral Production Platform

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)37968-0
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

Production of Bioengineered Outer Membrane Vesicles as a Vaccine Platform

English

Perioperative Management of Hemophilia a Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Decellularized Scaffolds as a Platform for Bioengineered Organs

Current Opinion in Organ Transplantation
AllergyImmunologyTransplantation
2014English

Elective Surgery on Factor VIII Inhibitor Patients Using Continuous Infusion of Recombinant Activated Factor VII

Thrombosis and Haemostasis
Hematology
2001English

AMulticenter Clinical Study of Recombinant Factor VIII (BL-160) in Hemophilia a Patients

Japanese Journal of Thrombosis and Hemostasis
1993English

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2012English

Who Should Be Liable for Funding Recombinant Factor VIII?

BMJ
1998English

Real-World Health Care Expenditure in Hemophilia a Patients Using Standard and Extended Half-Life Recombinant Factor VIII Products

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes

Molecular Therapy - Methods and Clinical Development
Molecular MedicineGeneticsMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy